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ABSTRACT 
Cancer can be described as the uncontrolled growth of abnormal cells. 5 Fluorouracil is an anticancer drug which has it effects on colon cancer, 
brain tumor, breast cancer, head & neck cancer. The aim of the present study was to find the targeting efficiency of the drug by molecular docking. 
The Protein- Ligand interaction plays a significant role in structural based drug designing. The drug, EGF and conjugation of drug and EGF were 
subjected to docking studies using the Argus Lab docking software to obtain the binding energy levels of each. The Drug with Epidermal Growth 
Factor (EGF) has higher binding energy of -107.649 with the responsible amino acids Cys6, gly12, Asp11, gly18, His13 when compared with the 
plain drug and plain EGF. 





About 13 percent of all the death worldwide is due to cancer, 
surpassing cardiovascular disease and taking number one place [1, 
2]. Chemotherapy of cancer is associated with various adverse 
effects viz. 
bone marrow depression, alopecia, drug induced caner, etc. and is 
often associated with cytotoxicity, genotoxicity to normal cells 
together with the development of resistance [3]. Medicinal chemists 
have great perseverance in research and development (R & D) for 
the search of newer and safer anticancer agents. EGFR family of 
Tyrosine Kinases (TK) play a vital role in cancer proliferation and it 
is suggested that any agent which would inhibit the TK activity may 
have substantial role in the cancer treatment [4]. So we selected 
EGFR family of TK and explore the binding mode of the compounds 
to EGFR tyrosine kinase active site. Family proteins were retrieved 
from the Protein Data Bank [5] and the compound was subjected to 
docking for binding capacity confirmation studies Computational 
Biology and bioinformatics have the potential not only of speeding 
up the drug discovery process thus reducing the costs, but also of 
changing the way drugs are designed. Rational Drug Design (RDD) 
helps to facilitate and speedup the drug designing process, which 
involves variety of methods to identify novel compounds. One such 
method is the docking of the drug molecule with the receptor 
(target). The site of drug action, which is ultimately responsible for 
the pharmaceutical effect, is a receptor [6]. Docking is the process by 
which two molecules fit together in 3D space. 
Methodology 
 
Targeting Efficiency studies by Insilico Analysis 
Bioinformatics is seen as an emerging field [7] with the 
potential to significantly improve how drugs are found, brought 
to the clinical trials and eventually released to the marketplace.  
Sequence retrieval 
Authentic structures for EGF and EGFR were retrieved from Protein 
data bank. Comparative availability of 3D structures was checked in 




Preparation of 5 fluorouracil  
5 fluorouracil structure was retrieved from PUBCHEM project 
database (http://pubchem.ncbi.nlm.nih.gov/), and conversion of 
SMILES to PDB files was done for generation of 2D structure of 5 
fluorouracil. The 2D model was optimized and energy minimized 
using clean geometry option in ArgusLab 4.0.1 (http: 
//www.ArgusLab. com) [8]. 
Ligand binding site prediction 
Ligand binding sites were calculated using Q site finder http:// 
www.modelling.leeds.ac.uk/ qsitefinder/, surface topology and the 
pocket information were also analyzed by the castP server 
http://sts-fw.bioengr.uic.edu/castp/calculation.php. Pocket 
detection and occupancy of the protein was set up using Q-Site 
Finder. Clefts were tarnished in the protein-surface using Q-
SiteFinder. The solvent available surface area (SASA) was found by 
the software server GETAREA http://curie.utmb.edu/getarea.html. 
The atomic Solvent Accessible Surface Area (SASA) enclosed by each 
cleft was calculated by utilizing radius of water probe 1.4 A0 and the 
area/ energy per residue was also designed. Dielectric constant was 
set to a value of 80.0, and Poisson-Boltzmann method of 
computation for 20 cycles was used for calculating the electrostatic 
potential in SWISS-PDB viewer. All the ligand binding residues were 
amongst hotspots as predicted by Meta-PPISP. Furthermore, PIC was 
made to use to calculate the nature of interaction occurring in the 
ligand binding residues. 
Docking studies 
Molecular docking software ArgusLab 4.0.1 was used for ligand 
docking on to EGF, EGFR and 5 Fluorouracil. Grid calculations during 
Argusdock with scoring function as Ascore for flexible ligand 
docking was performed with grid calculations 15.00, 15.00, and 
15.00, respectively, with grid resolution  
of 0.400 A°. 
Assessment of protein-ligand interaction 
Hydrogen bond interactions were calculated by using Discovery 
studio (http://accelrys.com/products/discovery-studio) and ligand 
map was generated using MOLEGRO. 
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Result & Discussion 
Ligand binding interaction assessment formed between EGFR and 5-
fluorouracil resulted in a sustainable complex when compared to 
EGF-5-Fluorouracil conjugate. Comparatively, the complex between 
EGFR and bound complex [9] showed better binding affinity 
patterns.5-FU docked in to the binding site (fig 3.1 and 3.2) of the 
EGF protein, EGFR protein individually and then the complex (EGF-
5FU) docked with the protein EGFR protein with the help of protein-
protein docking algorithm. The table 3.1 shows that active site 
amino acids responsible for forming complex. 
 
Table 3.1: Hydrophobic Interactions 
Name of the complex Docking energy Responsible Amino acids 
EGF-5FU -59.175 Cys6,gly12,Asp11, gly18 
EGFR-5FU -20.855 Gly 18 
COMPLEX(EGF-5FU)+EGFR -107.649 Cys6,gly12,Asp11, gly18, His13 
 
 











Fig 3.2: EGFR-5FU COMPLEX 
 
Table 3.2:Protein –Protein dock 
 
Table 3.2 shows the binding energy of the docked molecules. 
Hydrophobic Interactions within 5 Angstroms showed distinct 
donor and acceptor atoms in protein complexes. The complexes 
visualized in MOLEGRO shows unique binding patterns. Figure 3.4 





Fig 3.3 Interacting aminoacid residues between EGF, EGFR and 
5FU 
 
Fig 3.4 ligand map showing interactions of hydrogen bond 
Incidently, there were no protein-protein aromatic-sulphur 
interactions and no protein-protein cation-pi interactions found 
[10]. Moreover, no protein-protein disulphide bridges are found. 
This docking studies shows that the complex (EGF-5FU) having the 
high dock score of -107.649 with the EGFR protein compare to other 
two docking complex. This docking study confirms that the EGF-5FU 
complex binds with EGFR tightly, and this improves the targeting 
efficiency, this study can be performed for Invivo studies for brain 
targeting.  
CONCLUSION 
The Protein-Ligand interaction plays a significant role in structural 
based drug designing. This docking study confirms that the EGF-5FU 
complex binds with EGFR tightly, and this improves the targeting 
efficiency, this study can be performed for Invivo studies for brain 
targeting.  
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